EyePoint (EYPT)
Develops sustained-release retinal therapies built around DURAVYU and Durasert E technology.
$3.87
vs last close−0.20 (−4.90%)
Something off on this page? Send us feedback.
Next report
Nov 4, 26
in 42 days
EPS estimate
−$0.91
Revenue estimate
$231.2K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.64−$0.65−$0.85−$0.85−$0.81−$0.99−$1.09Pending
Estimate−$0.54−$0.65−$0.67−$0.77−$0.78−$0.79−$1.01−$0.91
Surprise−18.5%0.0%−26.9%−10.4%−3.8%−25.3%−7.9%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$11.6M$24.5M$5.3M$966.0K$620.0K$696.0K$507.0KPending
Estimate$8.2M$6.8M$4.1M$1.0M$994.5K$352.8K$451.2K$231.2K
Surprise+41.5%+258.4%+29.2%−4.0%−37.7%+97.3%+12.4%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.70 | — | — |
| Sep 2027 | −$0.56 | — | — |
| Jun 2027 | −$0.60 | — | — |
| Mar 2027 | −$0.74 | — | — |
| Dec 2026 | −$0.82 | — | — |
| Nov 2026 | −$0.91 | — | — |
| Aug 2026 | −$1.01 | −$1.09 | −7.9% |
| May 2026 | −$0.79 | −$0.99 | −25.3% |
| Mar 2026 | −$0.78 | −$0.81 | −3.8% |
| Nov 2025 | −$0.77 | −$0.85 | −10.4% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Sep 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Sep 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Sep 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Sep 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.70 | — | — | $438.7K | — | — | — |
| Sep 2027 | −$0.56 | — | — | $125.0K | — | — | — |
| Jun 2027 | −$0.60 | — | — | $125.0K | — | — | — |
| Mar 2027 | −$0.74 | — | — | $338.7K | — | — | — |
| Dec 2026 | −$0.82 | — | — | $301.1K | — | — | — |
| Nov 4, 2026 | −$0.91 | — | — | $231.2K | — | — | — |
| Aug 5, 2026 | −$1.01 | −$1.09 | −7.9% | $451.2K | $507.0K | +12.4% | +5.0% |
| May 6, 2026 | −$0.79 | −$0.99 | −25.3% | $352.8K | $696.0K | +97.3% | −2.9% |
| Mar 4, 2026 | −$0.78 | −$0.81 | −3.8% | $994.5K | $620.0K | −37.7% | −1.8% |
| Nov 5, 2025 | −$0.77 | −$0.85 | −10.4% | $1.0M | $966.0K | −4.0% | −11.1% |
| Aug 6, 2025 | |||||||
| May 7, 2025 | |||||||
| Mar 5, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 7, 2024 | |||||||
| May 8, 2024 | |||||||
| Mar 7, 2024 | |||||||
| Nov 1, 2023 | |||||||
| Aug 2, 2023 | |||||||
| May 3, 2023 | |||||||
| Mar 2, 2023 | |||||||
| Nov 2, 2022 | |||||||
| Aug 3, 2022 | |||||||
| May 4, 2022 | |||||||
| Mar 3, 2022 | |||||||
| Nov 3, 2021 | |||||||
| Aug 4, 2021 | |||||||
| May 5, 2021 | |||||||
| Mar 4, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 5, 2020 | |||||||
| May 6, 2020 | |||||||
| Mar 5, 2020 | |||||||
| Nov 7, 2019 | |||||||
| Aug 7, 2019 | |||||||
| May 8, 2019 | |||||||
| Mar 14, 2019 | |||||||
| Nov 6, 2018 | |||||||
| Sep 12, 2018 | |||||||
| May 8, 2018 | |||||||
| Feb 7, 2018 | |||||||
| Nov 7, 2017 | |||||||
| Sep 11, 2017 | |||||||
| May 4, 2017 | |||||||
| Feb 7, 2017 | |||||||
| Nov 7, 2016 | |||||||
| Sep 12, 2016 | |||||||
| May 5, 2016 | |||||||
| Feb 8, 2016 | |||||||
| Nov 5, 2015 | |||||||
| Sep 9, 2015 |